Bold Insight and The Office of Experience partner to deliver outstanding user experiences.
Back to team page
Katie Leyden
Senior UX Researcher
Katie’s background in human-centered design, cultural analysis, and business positions her as both a creative and strategic thinker. She brings a cross-disciplinary understanding to ethnographic research and business analysis and has focused on various sectors including technology, e-commerce, entrepreneurship, and housing. She is driven by the desire to understand why people think the way they do and to find solutions for the everyday inconveniences. Katie graduated with a BA from the University of Notre Dame in American Studies with minors in Business Economics and Collaborative Innovation.
Bold facts
Learn more about
Something unique about you summed up in one sentence:
Your favorite part of working at Bold Insight
In your spare time (or if you had spare time), you would absolutely do this:
Your favorite city in the world is...and why?
You cannot start the day without doing this:
Your ultimate celebrity dinner party guest list would include:
Long-term personal or professional goal?
Any other facts to share?
Read our team’s latest bold insights
When designing an experience, are you really thinking about the customer first?
While every organization has constraints to consider when designing experiences for customers or users, designing the ideal customer experience is completely possible within those constraints. Begin by identifying the experience you want your customer to have and work “backward” from there.
UX project logistics: choosing the right vendors for project success
Selecting the correct vendors to support your UX project is critical to success. From facilities to recruiting, knowing the right questions to ask, budget constraints, and client needs and expectations will make the selection process smooth and painless.
Reclassifying diabetes: 3 implications for product design
Recent research suggests that reclassifying diabetes may allow for the development of more targeted diabetes treatments. This could present opportunities to design these treatments to maximize patient safety and experience.